M&A Deal Summary |
|
|---|---|
| Date | 2016-02-22 |
| Target | Bristol-Myers - HIV R&D portfolio |
| Sector | Life Science |
| Buyer(s) | ViiV Healthcare |
| Sellers(s) | Bristol-Myers Squibb |
| Deal Type | Divestiture |
| Deal Value | 350M USD |
SEARCH BY
ViiV Healthcare is a global specialist HIV company.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science M&A | 1 of 1 |
| Type: Divestiture M&A Deals | 1 of 1 |
| Country: United States M&A | 1 of 1 |
| Year: 2016 M&A | 1 of 1 |
| Size (of disclosed) | 1 of 1 |
| Category | Company |
|---|---|
| Founded | 1887 |
| Sector | Life Science |
| Employees | 34,100 |
| Revenue | 48.3B USD (2024) |
Bristol-Myers Squibb is a life science company engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis. Bristol-Myers Squibb was incorporated in 1887 and is based in Princeton, New Jersey.
| DEAL STATS | # |
|---|---|
| Overall | 8 of 13 |
| Sector: Life Science M&A | 2 of 5 |
| Type: Divestiture M&A Deals | 6 of 9 |
| Country: United States M&A | 7 of 8 |
| Year: 2016 M&A | 1 of 1 |
| Size (of disclosed) | 6 of 6 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2015-11-02 |
Cardioxyl Pharmaceuticals
Chapel Hill, North Carolina, United States Cardioxyl Pharmaceuticals, Inc. is a developer of novel therapeutic agents for the treatment of cardiovascular disease. |
Buy | $300M |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2016-03-23 |
Padlock Therapeutics
Cambridge, Massachusetts, United States Padlock Therapeutics, Inc. is a biotechnology company dedicated to creating new medicines to treat destructive autoimmune diseases. |
Buy | $225M |
